MHC-I-negative cases among patients with DLBCL are significantly more prevalent than negative cases owing to B2M mutations (75% vs. 43%, respectively), suggesting the existence of additional causes of the downregulation of MHC expression (Ennishi, Takata, et al., 2019). The gene discussed is B2M; the disease is diffuse large B-cell lymphoma.